Skip to main content
THMO logo

ThermoGenesis Holdings, Inc. (THMO) Stock Price & Analysis

ThermoGenesis Holdings, Inc. (THMO) — price $0.0001 (0.00%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.0001 $0.00 (0.00%)

ThermoGenesis Holdings, Inc. · THMO

ThermoGenesis Holdings, Inc. is a leading innovator in automated cell processing systems for medical applications.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • FATE · Fate Therapeutics, Inc. · 15 /100
  • AEMD · Aethlon Medical, Inc. · 31 /100
  • HYPD · Hyperion DeFi, Inc. · 39 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0001
Change on the day0.00%
52-week range$0.0001 – $0.0001
Shares traded on the day100

Price & events

Other perspectives

Council score for ThermoGenesis Holdings (THMO): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Negative
Gross Margin Weak

Read on: Jul 16, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Jul 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is ThermoGenesis Holdings (THMO), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ThermoGenesis Holdings, Inc. (THMO) is the company analyzed here. It employs 25 people and is led by Xiaochun Xu. In Q1 FY2024 it reported revenue of $3M and net income of -$2M.

2 · Latest results

What do the latest results show for ThermoGenesis Holdings (THMO)?

Short answer · as of

The most recent reported quarter, Q1 FY2024, carried revenue of $3M. Against analyst estimates the company has EPS beat 1 of the last 8 reports.

Quarterly income statement — 1 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q1 FY2024$3M-$2M-$0.46 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for ThermoGenesis Holdings (THMO)?

Short answer · as of

The distress and quality screens read Altman Z -41.88 · Piotroski F 3. Trailing ratios: current ratio 0.44.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -41.88 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at ThermoGenesis Holdings (THMO)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $24.61M · EPS 0.31 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q1 FY2024) was filed May 17, 2024 — 24 months ago.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$24.61M
EPS estimate
$0.31

Measured against a quoted price of $0.0001 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
3
Purchases
0
Sales
1
Other transactions
11

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held THMO in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported THMO in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About THMO

These answers are editorial: 1 of these 1 answer is drawn from the THMO research dossier (written Jun 15, 2026 by gpt-4o-mini). Figures in this section are not part of the source register.

What are the main risks for THMO?

ThermoGenesis Holdings, Inc. faces several risks, including regulatory challenges that may delay product approvals and market entry. Additionally, the company has a high operational loss margin, which could affect its financial stability.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 8 from Financial Modeling Prep (FMP) and 9 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.